Clinical trials: Meningococcal
Vaccines, Pneumococcal
Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with routine paediatric vaccinations…
- Trial name
- NCT00474539
- Testing
- 13-valent pneumococcal conjugate vaccine, 7-valent pneumococcal conjugate vaccine
- Where
- 27 sites in Spain
- Volunteers
- 449 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Meningitis, Meningococcal Infection
Dose Comparison Study of Menactra® in US Children
To explore the potential benefit of the administration of Menactra vaccine as a two-dose regimen to children. Primary Objective: To assess, by age group, the immune response to Menactra vaccine after each vaccine injection.
- Conditions
- Meningitis, Meningococcal Infection, Neisseria Meningitidis
- Trial name
- NCT00700635
- Testing
- Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate
- Where
- 15 sites in United States
- Volunteers
- 333 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Hand, Foot and Mouth Disease
Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With EPI Vaccines
The purpose of this study is to evaluate the safety and immunogenicity of concomitant administration of EV71 vaccine with recombinant hepatitis B vaccine/Group A meningococcal polysaccharide vaccine.
- Trial name
- NCT03274102
- Testing
- Concomitant administration of EV71 vaccine with EPI vaccines, Single injection of EPI vaccine, EV71 Vaccine only
- Where
- China
- Volunteers
- 780 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Infections, Meningococcal
Study to Evaluate Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 18-25 Years
The purpose of this study is to evaluate the safety, reactogenicity, immunogenicity and persistence up to three years after administration of one dose of the MenACWY conjugate vaccine when given to young adults aged 18-25 years.
- Trial name
- NCT00196950
- Testing
- Meningococcal (vaccine)
- Where
- Belgium
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningitis, Meningococcemia
Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine
This study was designed to simulate meningococcal challenge by vaccination with a fractional combined dose of unconjugated meningococcal polysaccharides A, C, Y, and W-135, Menomune® in children who were vaccinated with one dose…
- Conditions
- Meningitis, Meningococcemia, Neisseria Meningitidis
- Trial name
- NCT00772070
- Testing
- A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)
- Where
- 8 sites in United States
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Invasive Meningococcal Disease
Can we Reduce the Number of Vaccine Injections for Children?
This open label randomised controlled study will evaluate the induction of immunity following varying schedules of vaccination with glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccines in infancy.
- Trial name
- MALTA (NCT01129518)
- Testing
- Glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccine, Routine schedule immunisations except monovalent MenC vaccine
- Where
- United Kingdom
- Volunteers
- 404 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Meningitis, Meningococcal
Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months
The purpose of this study is to evaluate the immunogenicity and safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in healthy volunteers aged from 3 to 5 months.
- Trial name
- NCT05252715
- Testing
- Meningococcal ACYW135 Polysaccharide Conjugate Vaccine, Meningococcal A and C Polysaccharide Conjugate Vaccine
- Where
- 2 sites in China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Meningitis, Meningococcal
A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age
MenACWY (Menveo) is a GSK vaccine intended for protection against disease caused by meningococcal bacteria groups A, C, W and Y in infants, children and adults, licensed in more than 60 countries.
- Trial name
- NCT03433482
- Testing
- MenACWY liquid, MenACWY
- Where
- 49 sites in Brazil, Estonia and 7 more
- Volunteers
- 1,707 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Meningococcal
Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine
The purpose of this study is to demonstrate, in 12-23 months old subjects, the non-inferiority of meningococcal vaccine GSK134612 co-administered with Infanrix hexa™, compared to each vaccine administered individually and to…
- Trial name
- NCT00508261
- Testing
- Meningococcal vaccine GSK134612, Infanrix™ hexa, Meningitec™
- Where
- 89 sites in Austria, Germany and 1 more
- Volunteers
- 793 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pertussis, Meningococcal Disease
Sources of COmplement in Meningococcal and Pertussis Serum Bactericidal Antibody Assays
This study is designed to allow cord blood sample collection from the cords of babies born in three gestational age windows: ≥37 gestational weeks, 32-36+6 gestational weeks and less than 32 gestational weeks to investigate…
- Conditions
- Pertussis, Meningococcal Disease, Prematurity
- Trial name
- COMPAre (NCT04023929)
- Testing
- Cord blood sampling
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- St George's, University of London
Meningococcal Disease
Safety Surveillance of MenACWY-CRM Vaccine in Children
The purpose of this study is to summarize the occurrence of incident serious medically attended events and events of interest up to 1 year following MenACWY-CRM vaccination administered as part of routine clinical care.
- Trial name
- NCT01452438
- Testing
- MenACWY-CRM
- Where
- United States
- Volunteers
- 393 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Infections, Meningococcal
Safety of 4CMenB Exposure During Pregnancy
4CMenB was approved by the Food and Drug Administration (FDA) in the United States in January 2015 for people aged 10 through 25 years of age.
- Trial name
- NCT02640677
- Testing
- 4CMenB
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- GlaxoSmithKline
Infections, Meningococcal, Meningococcal Vaccines
Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects
The purpose of this study is to demonstrate, in 2-10 year old subjects, the non-inferiority of meningococcal vaccine GSK134612 compared to licensed meningococcal vaccine Mencevax™.
- Trial name
- NCT00514904
- Testing
- Nimenrix, Mencevax
- Where
- 7 sites in India, Lebanon and 2 more
- Volunteers
- 1,504 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningococcal Disease
A Study to Learn About the Safety of PENBRAYA During Pregnancy
This study is a pregnancy registry designed to learn more about the safety of the study vaccine PENBRAYA (a vaccine that protects against meningitis causing bacteria) when it is given during pregnancy or within 30 days before the…
- Trial name
- NCT07768163
- Testing
- PENBRAYA
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Pfizer
Vaccination
A Phase IV Study to Evaluate the Immunogenicity and Safety in UK Laboratory Workers of Menitorix
Menitorix is a combined Hib conjugate and meningococcal C conjugate vaccine made by GlaxoSmithKline. It is currently licensed and recommended as a booster vaccination for UK children in the second year of life.
- Trial name
- NCT00503165
- Testing
- Menitorix (MenC and Hib conjugate)
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Public Health England
Meningitis, Meningococcal
Ciprofloxacin for the Prevention of Meningococcal Meningitis 2018
The trial is an interventional, cluster-randomized trial to assess the impact of oral ciprofloxacin for household and community contacts of meningitis cases on the incidence of meningitis during an epidemic.
- Trial name
- NCT03431675
- Testing
- Ciprofloxacin
- Where
- Niger
- Volunteers
- healthy volunteers welcome
- Sponsor
- Epicentre
Meningococcal Disease
Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine
The primary purpose of this study is to evaluate the persistence of bactericidal antibodies in children of approximately 22 to 45 months of age previously enrolled in the V59P22 study (NCT00667602) who received Novartis MenACWY…
- Trial name
- NCT01345721
- Testing
- MenACWY-CRM
- Where
- 11 sites in Germany
- Volunteers
- 205 people
- Sponsor
- Novartis Vaccines
Meningococcal Disease, Meningococcal Meningitis
Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines
This study will evaluate safety, tolerability, and immunogenicity of a booster dose of a meningococcal vaccine formulation in adolescents.
- Trial name
- NCT01367158
- Testing
- Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine, Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Tdap
- Where
- 7 sites in Chile, Colombia and 1 more
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Neisseria Meningitidis, Haemophilus Influenzae Type b
Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals' Hib-MenCY-TT (MenHibrix®) vaccine co-administered with Rotarix, Prevnar 13 and Havrix as compared to PedvaxHIB…
- Trial name
- NCT01978093
- Testing
- Hib-MenCY-TT (MenHibrix®), Pediarix®, Rotarix®
- Where
- 26 sites in United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Gonorrhea, Sexually Transmitted Infection
Efficacy Trial on Meningococcal B Vaccine for Preventing Gonorrhea Infections
Objectives: Efficacy of a meningococcal vaccine against Neisseria gonorrhoea (NG) infection among men who have sex with men (MSM). Design: Parallel randomised double-blind placebo-controlled trial.
- Trial name
- NCT05766904
- Testing
- 4CMenB vaccine
- Where
- Hong Kong
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong